An observational study in Alzheimer s Disease, MCI Conversion to Dementia and pTau217, sponsored by Neurogen Biomarking LLC. Recruiting at 5 sites in United States. Open to participants aged 40 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Neurogen Biomarking LLC · Observational
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 751 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →This is the only study on the registry with Neurogen Biomarking LLC as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Adults aged 40-90 recruited through clinical records review, advertising, and community outreach, including AD patients, cognitively healthy controls, and non-AD cognitively impaired individuals with confirmed amyloid-negative status. A subset has amyloid pathology confirmed via PET or CSF.
Exclusion Criteria:
Amyloid PET/CSF confirmed and clinically diagnosed
No history of cognitive impairment
Cognitive impairment not due to AD, confirmed amyloid-negative via PET/CSF
Agreement between p-tau217 concentration in Tasso device capillary blood and venipuncture blood
Mean, mean fold-change, and effect size of p-tau217 in Tasso samples between AD and non-AD groups.
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.